GLP1R and obesity disorder: In addition, researchers have found out that glucagon-like peptide-1 receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists such as tirzepatide are currently the best obesity drugs available [8,9].